![conference banner](/images/conference-banner.jpeg)
Abstract
Multidrug resistant tuberculosis (MDR TB) is defined as resistance to isoniazid and rifampicin. The recent Global Project on drug-resistant TB confirmed that multidrug-resistant TB was found in all regions of the world. Misdiagnosis of MDR tuberculosis due to laboratory related errors has been reported recently and hence susceptibility results alone should not dictate treatment and careful clinical correlation is necessary. Drug-susceptible TB can be cured in six to eight months with first-line anti-TB drugs. However, incorrect or partial treatment results in drug-resistant TB. WHO has recommended that multidrug resistant tuberculosis should be considered after failure of fully supervised category II or I treatment regimen. In a retrospective study of 55 cases of MDR pulmonary TB referred to our centre treated with kanamycin, ethionamide, cycloserine and PAS (KCEP) +/- quinolones, 38 (69.09%) patients completed treatment, 11 defaulted and 6 died. 31/38 (81.57%) cases were cured and 7/38 (18.4%) failed on therapy. All cases that failed had received one or more second line drugs previously. The cost of treatment ranged from $1000 to $3000. Adverse drug effects were seen in 8/55 patients (14.54%). Second line drugs for tuberculosis have been now listed under the WHO essential drugs list and are available through the Green Light Committee. Adherence to the strict guidelines will result in proper management of existing cases of MDRTB.
Keywords: Laboratory errors, second line therapy, Multidrug-resistant tuberculosis
Current Respiratory Medicine Reviews
Title: Multi-Drug Resistant Pulmonary Tuberculosis
Volume: 2 Issue: 1
Author(s): J. M. Joshi and D. Gothi
Affiliation:
Keywords: Laboratory errors, second line therapy, Multidrug-resistant tuberculosis
Abstract: Multidrug resistant tuberculosis (MDR TB) is defined as resistance to isoniazid and rifampicin. The recent Global Project on drug-resistant TB confirmed that multidrug-resistant TB was found in all regions of the world. Misdiagnosis of MDR tuberculosis due to laboratory related errors has been reported recently and hence susceptibility results alone should not dictate treatment and careful clinical correlation is necessary. Drug-susceptible TB can be cured in six to eight months with first-line anti-TB drugs. However, incorrect or partial treatment results in drug-resistant TB. WHO has recommended that multidrug resistant tuberculosis should be considered after failure of fully supervised category II or I treatment regimen. In a retrospective study of 55 cases of MDR pulmonary TB referred to our centre treated with kanamycin, ethionamide, cycloserine and PAS (KCEP) +/- quinolones, 38 (69.09%) patients completed treatment, 11 defaulted and 6 died. 31/38 (81.57%) cases were cured and 7/38 (18.4%) failed on therapy. All cases that failed had received one or more second line drugs previously. The cost of treatment ranged from $1000 to $3000. Adverse drug effects were seen in 8/55 patients (14.54%). Second line drugs for tuberculosis have been now listed under the WHO essential drugs list and are available through the Green Light Committee. Adherence to the strict guidelines will result in proper management of existing cases of MDRTB.
Export Options
About this article
Cite this article as:
Joshi M. J. and Gothi D., Multi-Drug Resistant Pulmonary Tuberculosis, Current Respiratory Medicine Reviews 2006; 2 (1) . https://dx.doi.org/10.2174/157339806775486146
DOI https://dx.doi.org/10.2174/157339806775486146 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
Call for Papers in Thematic Issues
Chronic obstructive pulmonary disease (COPD) from childhood to adulthood: from the past to the future
Chronic obstructive pulmonary disease (COPD) is one of the three leading causes of death worldwide, with a major prevalence in low- and middle-income countries, resulting in a high social and economic cost. It is a heterogeneous respiratory disease, treatable and preventable, that causes persistent and often progressive airway obstruction in ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Incidental Extracardiac Findings on Coronary Computed Tomography Angiography: A Pictorial Review of Imaging Findings
Current Medical Imaging Antibacterial and Antibiofilm Potentials of Marine Pyrrole-2-Aminoimidazole Alkaloids and their Synthetic Analogs
Mini-Reviews in Medicinal Chemistry Antibacterial Function of the Human Cathelicidin-18 Peptide (LL-37) between Theory and Practice
Protein & Peptide Letters Mycotherapy of Cancer: An Update on Cytotoxic and Antitumor Activities of Mushrooms, Bioactive Principles and Molecular Mechanisms of their Action
Current Topics in Medicinal Chemistry Radiolabeled Probes Targeting G-Protein-Coupled Receptors for Personalized Medicine
Current Pharmaceutical Design Novel Diazenyl Containing Phenyl Styryl Ketone Derivatives As Antimicrobial Agents
Anti-Infective Agents Fatty Acid Biosynthesis: An Updated Review on KAS Inhibitors
Current Drug Discovery Technologies Design, Synthesis, SAR Study, Antimicrobial and Anticancer Evaluation of Novel 2-Mercaptobenzimidazole Azomethine Derivatives
Mini-Reviews in Medicinal Chemistry “Self-Antigenic Universe” and Tuberculosis Vaccine Development
Current Pharmacogenomics and Personalized Medicine Community Expansion and Gene Geography of Sickle Cell Trait and G6PD Deficiency, and Natural Selection against Malaria: Experience from Tribal Land of India
Cardiovascular & Hematological Agents in Medicinal Chemistry Anti-Tuberculosis
Current Bioactive Compounds Metal Complexes, their Cellular Targets and Potential for Cancer Therapy
Current Pharmaceutical Design The Role of Anti-Inflammatory Drugs in Respiratory Diseases - Pirfenidone, Penicillamine, Chloroquine and Chlorambucil
Current Respiratory Medicine Reviews Therapeutic Potential of Plant Extracts and Phytochemicals Against Brain Ischemia-Reperfusion Injury: A Review
The Natural Products Journal Recent Advances in the Synthesis and Development of Curcumin, its Combinations and Formulations and Curcumin-like Compounds as Anti-infective Agents
Current Medicinal Chemistry Virtual Screening: Are We There Yet?
Mini-Reviews in Medicinal Chemistry Activation of Macrophages: Establishing a Role for Polysaccharides in Drug Delivery Strategies Envisaging Antibacterial Therapy
Current Pharmaceutical Design Potential Strategies for Minimizing Mechanism-Based Inhibition of Cytochrome P450 3A4
Current Pharmaceutical Design Curcumin Activates Erythrocyte Membrane Acetylcholinesterase
Letters in Drug Design & Discovery Calcium Antagonists: A Ready Prescription for Treating Infectious Diseases?
Current Topics in Medicinal Chemistry